Insider holders · CIK 0000872589
REGENERON PHARMACEUTICALS, INC. · REGN
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| Sanofi10% Owner | 20,723,717 | 2,799,552 | 23,523,269 | Mar 12, 2019 · 8:19 pm EDT | Form 4 |
| Leonard S SchleiferPresident & CEO | 423,962 | 5,754 | 429,716 | Dec 14, 2018 · 4:19 pm EST | Form 4 |
| George YancopoulosPresident and Chief Scientific | 0 | 400,000 | 400,000 | Dec 17, 2018 · 4:02 pm EST | Form 4 |
| P Roy VagelosChairman of the Board | 314,877 | 1,203 | 316,080 | Dec 14, 2018 · 4:49 pm EST | Form 4 |
| George L SingDirector | 115,095 | 10,000 | 125,095 | Jan 4, 2019 · 4:12 pm EST | Form 4 |
| Neil StahlEVP Research and Development | 31,973 | 5,673 | 37,646 | May 25, 2018 · 4:03 pm EDT | Form 4 |
| Joseph J LarosaEVP General Counsel and Secret | 36,373 | 413 | 36,786 | Aug 21, 2026 · 4:01 pm EDT | Form 4 |
| Peter PowchikSVP Clinical Development & Reg | 25,714 | 1,674 | 27,388 | Dec 19, 2016 · 4:15 pm EST | Form 4 |
| Robert J TerifayEVP Commercial | 25,214 | 1,699 | 26,913 | Aug 11, 2017 · 4:02 pm EDT | Form 4 |
| Christopher R. FenimoreEVP Finance CFO | 19,984 | 25 | 20,009 | Aug 20, 2026 · 4:01 pm EDT | Form 4 |
| Robert E LandrySVP Finance & CFO | 17,348 | 109 | 17,457 | Dec 14, 2018 · 4:08 pm EST | Form 4 |
| Arthur F RyanDirector | 17,303 | — | 17,303 | Jul 7, 2026 · 4:05 pm EDT | Form 4 |
| Michael S BrownDirector | 323 | 12,349 | 12,672 | Jan 4, 2019 · 4:13 pm EST | Form 4 |
| Joseph L GoldsteinDirector | 12,323 | — | 12,323 | Jan 11, 2019 · 4:06 pm EST | Form 4 |
| Marion McCourtEVP Commercial | 12,003 | 219 | 12,222 | Sep 3, 2026 · 4:50 pm EDT | Form 4 |
| Douglas S McCorkleVP Controller and Asst Treasur | 6,866 | 4,129 | 10,995 | Dec 29, 2015 · 7:44 pm EST | Form 4 |
| Charles A BakerDirector | 9,000 | — | 9,000 | Oct 3, 2017 · 4:00 pm EDT | Form 4 |
| Alfred G GilmanDirector | 8,912 | — | 8,912 | Aug 7, 2015 · 6:15 pm EDT | Form 4 |
| Michael S AbermanSVP Strategy Investor Relation | 4,693 | 448 | 5,141 | Jun 23, 2017 · 4:10 pm EDT | Form 4 |
| Daniel P Van PlewEVP & General Mgr Industrial O | 1,921 | 1,444 | 3,365 | May 19, 2016 · 4:26 pm EDT | Form 4 |
| Huda Y ZoghbiDirector | 1,703 | — | 1,703 | Aug 12, 2026 · 4:14 pm EDT | Form 4 |
| Marc Tessier-LavigneDirector | 1,510 | — | 1,510 | Jan 4, 2019 · 4:03 pm EST | Form 4 |
| Robert Alexander IngramDirector | 1,500 | — | 1,500 | May 27, 2015 · 4:02 pm EDT | Form 4 |
| Christine A PoonDirector | 1,113 | — | 1,113 | Jan 4, 2019 · 4:13 pm EST | Form 4 |
| Kathryn GuariniDirector | 603 | — | 603 | Sep 3, 2026 · 4:47 pm EDT | Form 4 |
| Bonnie L BasslerDirector | 323 | — | 323 | Jan 4, 2019 · 4:04 pm EST | Form 4 |
| N Anthony ColesDirector | 323 | — | 323 | Jan 4, 2019 · 4:08 pm EST | Form 4 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.